Amarantus Bioscience Valuation Multiples

Discover revenue and EBITDA valuation multiples for Amarantus Bioscience and similar public comparables like Vicarious Surgical, SensoDetect, MyndTec, Arrayit and more.

Amarantus Bioscience Overview

About Amarantus Bioscience

Amarantus Bioscience Holdings Inc is a biopharmaceutical company. It is focused on developing therapeutic products for orphan drug designation in the areas of neurology, psychiatry, ophthalmology and regenerative medicine, and diagnostics in neurology. The company's prime therapeutic program, eltoprazine is a small molecule indicated for the treatment of Levodopa-induced dyskinesia. The group's diagnostics division is dedicated to the development and commercialization of neurology diagnostic products. Its diagnostic product, LymPro Test is a blood-based assay to diagnose Alzheimer's disease.


Founded

2008

HQ

United States

Employees

5

Financials (FY)

Revenue: -
Net Income: ($25M)

EV

$315K

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Amarantus Bioscience Financials

Amarantus Bioscience reported last fiscal year revenue of -.

In the same fiscal year, Amarantus Bioscience generated had net loss of ($25M).


Amarantus Bioscience P&L

In the most recent fiscal year, Amarantus Bioscience reported revenue of - and net income of ($25M).

Amarantus Bioscience is unprofitable as of last fiscal year, with net margin of -.

See analyst estimates for Amarantus Bioscience
Last FY202620272028
Net Profit($25M)
Net Debt$3M

Financial data powered by Morningstar, Inc.

Amarantus Bioscience Stock Performance

Amarantus Bioscience has current market cap of $315K, and enterprise value of $315K.

EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$315K$315K-----

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Amarantus Bioscience Valuation Multiples

Amarantus Bioscience Financial Valuation Multiples

As of August 21, 2026, Amarantus Bioscience has market cap of $315K and EV of $315K.

Amarantus Bioscience has a P/E ratio of (0.0x).

Last FY202620272028
EV/EBIT(0.0x)
P/E(0.0x)
EV/FCF(0.0x)

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Amarantus Bioscience Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Amarantus Bioscience Operational KPIs

Amarantus Bioscience's revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $5.0M for the same period.

Access forward-looking KPIs for Amarantus Bioscience
Last FY202620272028
Revenue per Employee$0.0M
Opex per Employee$5.0M

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Amarantus Bioscience Competitors

Amarantus Bioscience competitors include Vicarious Surgical, SensoDetect, MyndTec, Arrayit, Longevity Health Holdings, Chordate Medical Holding, Easton Pharmaceuticals, Remedent, Evome Medical and EvokAI.

Most Amarantus Bioscience public comparables operate across Diagnostics & Genomics, Medical Devices, BioTech and DeepTech.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Vicarious Surgical--(0.1x)-
SensoDetect----
MyndTec4.5x-(0.4x)-
Arrayit0.0x-(0.0x)-
Longevity Health Holdings0.4x-(0.1x)-
Chordate Medical Holding----
Easton Pharmaceuticals----
Remedent0.0x-(0.0x)-

This data is available for Pro users. Sign up to see all Amarantus Bioscience competitors and their valuation data.

Start Free Trial

Amarantus Bioscience VC Funding History

Before going public, Amarantus Bioscience raised $4M in total equity funding, across 2 rounds.


Amarantus Bioscience Funding Rounds

DateStageInvestorsRaisedValuationRev. MultipleDeal Summary
Nov-14Seed-$3M-Amarantus BioScience Holdings closed a $5 million investment round on approximately November 17, 2014, from Discover Growth Fund via issuance of Series G preferred stock convertible at $0.06 per common share. The company develops diagnostics and treatments for neurological, psychiatric, ophthalmologic diseases, and regenerative medicine. Funds were allocated to advance neurology diagnostic products, therapeutic drug candidates, and working capital.
Aug-13Seed-$1M--

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Amarantus Bioscience

When was Amarantus Bioscience founded?Amarantus Bioscience was founded in 2008.
Where is Amarantus Bioscience headquartered?Amarantus Bioscience is headquartered in United States.
How many employees does Amarantus Bioscience have?As of today, Amarantus Bioscience has over 5 employees.
Is Amarantus Bioscience publicly listed?Yes, Amarantus Bioscience is a public company listed on OTCM.
What is the stock symbol of Amarantus Bioscience?Amarantus Bioscience trades under AMBS ticker.
When did Amarantus Bioscience go public?Amarantus Bioscience went public in 2008.
Who are competitors of Amarantus Bioscience?Amarantus Bioscience main competitors include Vicarious Surgical, SensoDetect, MyndTec, Arrayit, Longevity Health Holdings, Chordate Medical Holding, Easton Pharmaceuticals, Remedent, Evome Medical, EvokAI.
What is the current market cap of Amarantus Bioscience?Amarantus Bioscience's current market cap is $315K.
Is Amarantus Bioscience profitable?No, Amarantus Bioscience is not profitable.
How many companies Amarantus Bioscience has acquired to date?Amarantus Bioscience hasn't acquired any companies yet (or none have been disclosed publicly).
In how many companies Amarantus Bioscience has invested to date?Amarantus Bioscience hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to Amarantus Bioscience

Lists including Amarantus Bioscience

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial